In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the treatment of wet age-related macular degeneration, according to a press release from Ocular Therapeutix.
“Despite advances in [neovascular age-related macular degeneration] treatment, there remains unpredictability around patient response to treatment, resulting in unsustainable burden and lack of adherence,” Pravin U. Dugel, MD, executive chairman, president and CEO of Ocular Therapeutix, told Healio. “In addition, fluid fluctuations and increased fibrosis lead to poor